AL-1095
![]() | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H22ClNO |
| Molar mass | 327.85 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| | |
AL-1095,[1] developed by Aldrich, is a centrally acting stimulant drug with comparable effects to amphetamine,[2] developed by Bristol in the 1970s.[3]
See also
References
- ↑ US 3506673, Warawa ED, Mueller NJ, "2-(4'Halo)-Benzhydryl-3-Quinuclidinols", issued 14 April 1970, assigned to Aldrich Chemical Company
- ↑ Hedblom P, Grinspoon L (1975). The Speed Culture: Amphetamine Use and Abuse in America. Cambridge: Harvard University Press. p. 50. ISBN 0-674-83192-6.
- ↑ Warawa EJ, Mueller NJ (January 1975). "Quinuclidine Chemistry. 3. β-cis-2-(4'-Chlorobenzhydryl)-3-quinuclidinol, a New Central Nervous System Stimulant. Importance of the Benzhydryl Configuration". Journal of Medicinal Chemistry. 18 (1): 71–4. doi:10.1021/jm00235a016. PMID 803245.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
